Vatalanib: the clinical development of a tyrosine kinase inhibitor of angiogenesis in solid tumours

Bibliography

• FOLKMAN J: Tumour angiogenesis: therapeutic implications. N. Engl. J. Med. (1971) 285(21):1182-1186.
   PubMed Web of Science ®Google Scholar
• TAKEBAYASHI Y, AKLYAMA S, YAMADA K et al.: Angiogenesis as an unfavourable prognostic factor in human colorectal carcinoma. Cancer (1996) 78(2):226-231.
   PubMed Web of Science ®Google Scholar
• ELLIS LM: Angiogenesis and its role in colorectal tumor and metastasis formation. Semin. Oncol. (2004) 31(Suppl. 17):3-9.
   PubMed Web of Science ®Google Scholar
• HURWITZ H, FEHRENBACHER L, NOVOTNY W et al.: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. (2004) 350(23):2335-2342.
   PubMed Web of Science ®Google Scholar
• HESS-STUMPP H, HABEREY M, THIERAUCH K-H: PTK 787/ZK 222584, a tyrosine kinase inhibitor of all known VEGF receptors, represses tumour growth with high efficacy. Chembiochem. (2005) 6(5):550-557.
   PubMed Web of Science ®Google Scholar
• WOOD JM, BOLD G, BUCHDUNGER E et al.: PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumour growth after oral administration. Cancer Res. (2000) 60(8):2178-2189.
   PubMed Web of Science ®Google Scholar
• SINI P, BAFFERT F, WOOD J, HYNES NE: Role of VEGFR signalling in tumor cells. 97th American Association for Cancer Research Annual Meeting. Washington, DC, USA (2006):2807 (Abstract).
   Google Scholar
• YANO S, HERBST RS, SHINOHARA H et al.: Treatment for malignant pleural effusion of human lung adenocarcinoma by inhibition of vascular endothelial growth factor receptor tyrosine kinase phosphorylation. Clin. Cancer Res. (2000) 6(3):957-965.
   PubMed Web of Science ®Google Scholar
• XU L, YONEDA J, HERRERA C, WOOD J, KILLION JJ, FIDLER IJ: Inhibition of malignant ascites and growth of human ovarian carcinoma by oral administration of a potent inhibitor of the vascular endothelial growth factor receptor tyrosine kinases. Int. J. Oncol. (2000) 16(3):445-454.
   PubMed Web of Science ®Google Scholar
• KITAGAWA Y, DAI J, ZHANG J et al.: Vascular endothelial growth factor contributes to prostate cancer-mediated osteoblastic activity. Cancer Res. (2005) 65(23):10921-9.
   PubMed Web of Science ®Google Scholar
• HESS C, VUONG V, HEGYI I et al.: Effect of VEGF receptor inhibitor PTK787/ZK222584 combined with ionizing radiation on endothelial cells and tumour growth. Br. J. Cancer (2001) 85(12):2010-2016.
   PubMed Web of Science ®Google Scholar
• BAKER CH, SOLORZANO CC, FIDLER IJ: Blockade of vascular endothelial growth factor receptor and epidermal growth factor receptor signalling for therapy of metastatic human pancreatic cancer. Cancer Res. (2002) 62(7):1996-2003.
   PubMed Web of Science ®Google Scholar
• KIM S, YAZICI YD, BARBER SE et al.: Growth inhibition of orthotopic anaplastic thyroid carcinoma xenografts in nude mice by PTK787/ZK222584 and CPT-11. Head Neck (2006) 28(5):389-399.
   Google Scholar
• LIN B, PODAR K, GUPTA D et al.: The vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584 inhibits growth and migration of multiple myeloma cells in the bone marrow microenvironment. Cancer Res. (2002) 62(17):5019-5026.
   PubMed Web of Science ®Google Scholar
• QIAN DZ, WANG X, KACHHAP SK et al.: The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584. Cancer Res. (2004) 64(18):6626-6634.
   PubMed Web of Science ®Google Scholar
• DREVS J, MULLER-DRIVER R, WITTIG C et al.: PTK787/ZK222584, a specific vascular endothelial growth factor-receptor tyrosine kinase inhibitor, affects the anatomy of the tumour vascular bed and the functional vascular properties as detected by dynamic enhanced magnetic resonance imaging. Cancer Res. (2002) 62(14):4015-4022.
   PubMed Web of Science ®Google Scholar
• YANG ZF, POON RT, LIU Y et al.: High doses of tyrosine kinase inhibitor PTK787 enhance the efficacy of ischemic hypoxia for the treatment of hepatocellular carcinoma: dual effects on cancer cell and angiogenesis. Mol. Cancer Ther. (2006) 5(9):2261-2270.
   PubMed Web of Science ®Google Scholar
• DREVS J, HOFFMAN I, HUGENSCHMIDT H et al.: Effects of PTK787/ZK222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumour, metastasis, vessel density and blood flow in a murine renal cell carcinoma model. Cancer Res. (2000) 60(17):4819-4824.
   PubMed Web of Science ®Google Scholar
• GOLDBRUNNER RH, BENDSZUS M, WOOD J, KIDERLEN M, SASAKI M, TONN JC: PTK787/ZK222584, an inhibitor of vascular endothelial growth factor receptor tyrosine kinases, decreases glioma growth and revascularization. Neurosurgery (2004) 55(2):426-432.
   PubMed Web of Science ®Google Scholar
• YAZICI YD, KIM S, JASSER SA et al.: Antivascular therapy of oral tongue squamous cell carcinoma with PTK787. Laryngoscope (2005) 115(12):2249-2255.
   PubMed Web of Science ®Google Scholar
• GEORGE D, OH W, GILLIGAN E et al.: Phase I study of the novel oral angiogenesis inhibitor PTK787/ZK222584:evaluating the pharmacokinetic effect of a high fat meal in patients with hormone refractory prostate cancer. Proceedings of the American Society of Clinical Oncology. New Orleans, USA (2004):4689 (Abstract).
   Google Scholar
• MROSS K, DREVS J, MULLER M et al.: Phase I clinical and pharmacokinetic study of PTK/ZK, a multiple VEGF receptor inhibitor, in patients with liver metastases from solid tumours. Eur. J. Cancer (2005) 41(9):1291-1299.
   PubMed Web of Science ®Google Scholar
• GUPTA P, MILLER AA, OWZAR K et al.: Pharmacokinetics of an oral VEGF receptor tyrosine kinase inhibitor (PTK787/ZK222584) in patients with myelodysplastic syndrome (MDS): Cancer and Leukaemia Group B Study 10105. Proceedings of the American Society of Clinical Oncology. Atlanta, USA (2006):6573 (Abstract).
   Google Scholar
• THOMAS AL, MORGAN B, HORSFIELD MA et al.: Phase I study of the safety, tolerability, pharmacokinetics and pharmacodynamics of PTK787/ZK222584 administered twice daily in patients with advanced cancer. J. Clin. Oncol. (2005) 23(18):4162-4171.
   PubMed Web of Science ®Google Scholar
• KNOBLICH J, PALDANIUS PM, GSCHWIND HP et al.: Clinical results from an ADME (absorption, distribution, metabolism, and excretion) trial of PTK787/ZK222584: a novel oral angiogenesis inhibitor in patients with advanced cancer. European Cancer Conference. Copenhagen, Denmark (2003):561 (Abstract).
   Google Scholar
• PAVEL M, SCHUPAN D, JOST L et al.: A Phase I open-label study with escalating doses of intravenous PTK787/ZK222584, a multi-VEGF receptor inhibitor, followed by multiple oral daily dosing to assess the absolute bioavailability of PTK787/ZK222584 after single and multiple doses in advanced cancer patients. European Cancer Conference. Paris, France (2005):1474 (Abstract).
   Google Scholar
• KOCH I, BARON A, ROBERTS S et al.: Influence of hepatic dysfunction on safety, tolerability and pharmacokinetics of PTK787/ZK222584 in patients with unresectable Hepatocellular carcinoma. Proceedings of the American Society of Clinical Oncology. Orlando, USA (2005):4134 (Abstract).
   Google Scholar
• TRARBACH T, SCHLEUCHER N, TEWES M et al.: Phase I/II study of PTK787/ZK222584, a novel oral angiogenesis inhibitor in combination with FOLFIRI as first line treatment for patients with metastatic colorectal cancer. Proceedings of the American Society of Clinical Oncology. Orlando, USA (2005):3605 (Abstract).
   Web of Science ®Google Scholar
• TEJPAR S, LIN E, BONO P et al.: A Phase IB, open-label, parallel design study of PTK787/ZK222584 in combination with irinotecan in patients with metastatic colorectal cancer to investigate the interaction between the agents. Proceedings of the American Society of Clinical Oncology. Orlando, USA (2005):3594 (Abstract).
   Web of Science ®Google Scholar
• THOMAS AL, TRARBACH T, BARTEL C et al.: A Phase IB, open-label dose-escalating study of the oral angiogenesis inhibitor PTK787/ZK 222584 (PTK/ZK), in combination with folfox4 chemotherapy in patients with advanced colorectal cancer. Ann. Oncol. (2007) (In Press).
   PubMedGoogle Scholar
• SCHRODER W, CAMPONE A, ABADIE S et al.: A Phase IB, open label, safety and pharmacokinetic study of escalating doses of PTK787/ZK222584 in combination with paclitaxel and carboplatin in patients with stage IIC to IV epithelial ovarian cancer. Proceedings of the American Society of Clinical Oncology. Atlanta, USA (2006):5075 (Abstract).
   Google Scholar
• KUO T, FITZGERALD H, KAISER B, SIKIC BI, FISHER A: A Phase I study of the VEGF receptor tyrosine kinase inhibitor vatalanib (PTK787/ZK222584) and gemcitabine in patients with advanced pancreatic cancer. Proceedings of the American Society of Clinical Oncology. Atlanta, USA (2006):127 (Abstract).
   Web of Science ®Google Scholar
• REARDON D, FRIEDMAN H, YUNG WKA et al.: A Phase I/II trial of PTK787/ZK222584, a novel oral angiogenesis inhibitor, in combination with either temozolomide or lomustine for patients with recurrent glioblastoma multiforme. Proceedings of the American Society of Clinical Oncology. New Orleans, USA (2004):1513 (Abstract).
   Web of Science ®Google Scholar
• GEORGE D, MICHAELSON D, OH WK et al.: A Phase I study of PTK787/ZK222584 in metastatic renal cell carcinoma. Proceedings of the American Society of Clinical Oncology. Chicago, USA (2003):1548 (Abstract).
   Web of Science ®Google Scholar
• FAVARO JP, GEORGE DJ: Targeted therapy in renal cell carcinoma. Expert Opin. Investig. Drugs (2005) 14(10):1251-1258.
   PubMed Web of Science ®Google Scholar
• GAULER TC, FISCHER B, SORIA J et al.: Phase II open-label study to investigate efficacy and safety of PTK787/ZK222584 orally administered once daily at 1,250mg as second-line monotherapy in patients with stage IIIb or stage IV non-small cell lung cancer. Proceedings of the American Society of Clinical Oncology. Atlanta, USA (2006):7195 (Abstract).
   Google Scholar
• ANTHONY LB, CRONIN M, O’DORISIO T, O’DORISIO S: An open-label Phase II study evaluating safety and efficacy of PTK787 in patients with progressive metastatic neuroendocrine cancer. Proceedings of the American Society of Clinical Oncology. Atlanta, USA (2006):14124 (Abstract).
   Google Scholar
• JOENSUU H, DE BRAUD F, COCO P et al.: A Phase II open-label study of PTK787/ZK222584 in the treatment of metastatic gastrointestinal stromal tumors (GISTs) resistant to imatinib mesylate. Proceedings of the American Society of Clinical Oncology. Atlanta, USA (2006):9531 (Abstract).
   Google Scholar
• MORGAN B, UTTING JF, HIGGINSON A et al.: A simple, reproducible method for monitoring the treatment of tumours using dynamic contrast-enhanced MR imaging. Br. J. Cancer (2006) 94:1420-1427
   PubMed Web of Science ®Google Scholar
• MORGAN B, THOMAS AL, DREVS J et al.: Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two Phase I studies. J. Clin. Oncol. (2003) 12(21):3955-3964.
   Google Scholar
• DREVS J, ZIRRGIEBEL U, SCHMIDT-GERSBACH CI et al.: Soluble markers for the assessment of biological activity with PTK787/ZK222584, a vascular endothelial growth factor receptor tyrosine kinase inhibitor in patients with advanced colorectal cancer from two Phase I trials. Ann. Oncol. (2005) 16(4):558-565.
   PubMed Web of Science ®Google Scholar
• HECHT JR, TRARBACH T, JAEGER J et al.: A randomised, double-blind, placebo-controlled, Phase III study in patients with metastatic adenocarcinoma of the colon or rectum receiving first line chemotherapy with oxaliplatin /5-fluorouracil/leucovorin and PTK787/ZK222584 or placebo (CONFIRM-1). Proceedings of the American Society of Clinical Oncology. Orlando, USA (2005):3 (Abstract).
   Web of Science ®Google Scholar
• KOEHNE C, BAJETTA E, LIN E et al.: Results of an interim analysis of a multinational randomized, double-blind, Phase III study in patients with previously treated metastatic colorectal cancer receiving FOLFOX4 and PTK787/ZK222584 or placebo (CONFIRM-2). Proceedings of the American Society of Clinical Oncology. Atlanta, USA (2006):7195 (Abstract).
   Google Scholar
• MAJOR P, TRARBACH T, LENZ H et al.: A meta-analysis of two randomised, double-blind, placebo-controlled Phase III studies in patients with metastatic colorectal cancer receiving FOLFOX 4 and PTK/ZK to determine clinical benefit on progression-free survival in high LDH patients. Proceedings of the American Society of Clinical Oncology. Atlanta, USA (2006):3529 (Abstract).
   Google Scholar
• KOUKOURAKIS MI, GIATROMANOLAKI A, SIVRIDIS E, GATTER KC, HARRIS AL: Lactate dehydrogenase 5 expression in operable colorectal cancer, strong association with survival and activated vascular endothelial growth factor pathway: a report of the Tumour Angiogenesis Research Group. J. Clin. Oncol. (2006) 24(26):877-885.
   Google Scholar
• AZUMA M, SHI MM, JACQUES CJ et al.: Tumor VEGFA gene expression is associated with serum lactate dehydrogenase levels and intratumoral mRNA expression of genes involved in glycolysis in patients with metastatic colorectal cancer. Proceedings of the American Society of Clinical Oncology. Atlanta, USA (2006):3530 (Abstract).
   Web of Science ®Google Scholar
• MOTZER RJ, HOOSEN S, BELLO CL, CHRISTENSEN JG: Sunitinib malate for the treatment of solid tumours: a review of the current clinical data. Expert Opin. Investig. Drugs (2006) 15(5):553-561.
   PubMed Web of Science ®Google Scholar
• FAIVRE S, DELBALDO C, VERA K et al.: Safety, pharmacokinetic and antitumour activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J. Clin. Oncol. (2006) 24(1):25-35.
   PubMed Web of Science ®Google Scholar
• DEMETRI G, VAN OOSTEROM AT, GARRETT C et al.: Improved survival and sustained clinical benefit with SU11248 in patients with GIST after failure of imatinib mesylate therapy in a Phase III trial. Proceedings of the American Society of Clinical Oncology. Atlanta, USA (2006):8 (Abstract).
   Web of Science ®Google Scholar
• MOTZER RJ, MICAHELSON MD, REMAN BG et al.: Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J. Clin. Oncol. (2006) 24(1):16-24.
   PubMed Web of Science ®Google Scholar
• SIU LL, AWADA A, TAKIMOTO CH et al.: Phase I trial of sorafenib and gemcitabine in advanced solid tumours with an expanded cohort in advanced pancreatic cancer. Clin. Cancer Res. (2006) 12(1):144-151.
   PubMed Web of Science ®Google Scholar
• ESCUDIER B, SZCZYLIK C, EISEN T et al.: Randomised Phase III trial of the RAF kinase and VEGFR inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma. Proceedings of the American Society of Clinical Oncology. Orlando, USA (2005):4510 (Abstract).
   Web of Science ®Google Scholar
• ROBOZ GJ, GILES FJ, LIST AF et al.: Phase I study of PTK787/ZK222584, a small molecule tyrosine kinase inhibitor, for the treatment of acute myeloid leukaemia ad myelodysplastic syndrome. Leukaemia (2006) 20(6):952-957.
   PubMed Web of Science ®Google Scholar
• BESSE B, GAULER T, FISCHER B et al.: Phase II open-label study to investigate efficacy and safety of PTK787/ZK222584 orally administered once daily or twice daily at 1250mg as second line monotherapy in patients with stage IIIB or stage IV non small cell lung cancer. Ann. Oncol. (2006) 17(S9):ix218-ix219 (Abstract 730PD).
   Google Scholar
• CASSIDY J, CLARKE S, RUBIO ED et al.: First efficacy and safety results from XELOX-1/NO16966, a randomised 2 × 2 factorial Phase III trial of XELOX versus FOLFOX4 + bevacizumab or placebo in first-line metastatic colorectal cancer. Ann. Oncol. (2006) 17(S9):LBA3 (Abstract).
   Web of Science ®Google Scholar
• GATENBY RA, GILLIES RJ: Why do cancers have high aerobic glycolysis? Nat. Rev. Cancer (2004) 4(11):891-899.
   PubMed Web of Science ®Google Scholar